Mednet Logo
CommunityMedical Oncology

How do you choose which BTK inhibitor to use in NHL?

Does the safety profile impact your choice significantly? Does your first choice vary by disease histology?
1 Answer
Mednet Member
Mednet Member
Hematology · University of California Irvine
Answered on

At this point, I use very little ibrutinib. If I need CNS penetration, ibrutinib has a track record there. Otherwise, I have pivoted to acalabrutinib and zanubrutinib. I typically will pick by indication - acala for CLL and zanu for WM/MZL. In MCL or likely soon in CLL, I am not entirely sure how to...

Join for free or sign in to see the full answer